Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.

Monico LB, Gryczynski J, Schwartz RP, Jaffe JH, O'Grady KE, Mitchell SG.

Am J Drug Alcohol Abuse. 2018 May 2:1-7. doi: 10.1080/00952990.2018.1461877. [Epub ahead of print]

PMID:
29718715
2.

Counseling Staff's Views of Patient-Centered Methadone Treatment: Changing Program Rules and Staff Roles.

Mitchell SG, Monico LB, Lertch E, Kelly SM, Gryczynski J, Jaffe JH, O'Grady KE, Schwartz RP.

J Behav Health Serv Res. 2018 Jul;45(3):506-515. doi: 10.1007/s11414-018-9603-1.

PMID:
29536342
3.

When does methadone treatment reduce arrest and severity of arrest charges? An analysis of arrest records.

Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O'Grady KE, Jaffe JH.

Drug Alcohol Depend. 2017 Nov 1;180:385-390. doi: 10.1016/j.drugalcdep.2017.08.025. Epub 2017 Sep 14.

PMID:
28961545
4.

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH.

J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4.

5.

Corrigendum to "A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans" [Drug Alcohol Depend. 128 (2013) 222-229].

Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK, Jaffe JH.

Drug Alcohol Depend. 2016 Nov 1;168:340. doi: 10.1016/j.drugalcdep.2016.09.011. Epub 2016 Sep 22. No abstract available.

6.

Corrigendum to "Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial." [Contemp. Clin. Trials 49 (2016): 21-28].

Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O'Grady KE, Jaffe JH.

Contemp Clin Trials. 2016 Nov;51:97. doi: 10.1016/j.cct.2016.09.008. Epub 2016 Oct 8. No abstract available.

PMID:
27729206
7.

Patient-centered methadone treatment: a randomized clinical trial.

Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O'Grady KE, Gandhi D, Olsen Y, Jaffe JH.

Addiction. 2017 Mar;112(3):454-464. doi: 10.1111/add.13622. Epub 2016 Nov 10.

8.

Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial.

Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, O'Grady KE, Jaffe JH.

Contemp Clin Trials. 2016 Jul;49:21-8. doi: 10.1016/j.cct.2016.06.002. Epub 2016 Jun 7.

9.

Relapse: What Should We Do About It? Commentary on Flynn and Brown (2016).

Jaffe JH.

J Subst Abuse Treat. 2016 May;64:5-6. doi: 10.1016/j.jsat.2015.12.010. Epub 2016 Feb 2. No abstract available.

PMID:
26906763
10.

Understanding Patterns Of High-Cost Health Care Use Across Different Substance User Groups.

Gryczynski J, Schwartz RP, O'Grady KE, Restivo L, Mitchell SG, Jaffe JH.

Health Aff (Millwood). 2016 Jan;35(1):12-9. doi: 10.1377/hlthaff.2015.0618.

11.

Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.

Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O'Grady KE, Jaffe JH.

Drug Alcohol Depend. 2015 Nov 1;156:133-138. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7.

12.

Heroin Use, HIV-Risk, and Criminal Behavior in Baltimore: Findings from Clinical Research.

Schwartz RP, Kelly SM, Gryczynski J, Mitchell SG, O'Grady KE, Jaffe JH.

J Addict Dis. 2015;34(2-3):151-61. doi: 10.1080/10550887.2015.1059222.

13.

Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes.

Monico LB, Gryczynski J, Mitchell SG, Schwartz RP, O'Grady KE, Jaffe JH.

J Subst Abuse Treat. 2015 Oct;57:89-95. doi: 10.1016/j.jsat.2015.05.005. Epub 2015 May 12.

14.

Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.

Monico LB, Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK, Jaffe JH.

J Subst Abuse Treat. 2015 Oct;57:57-62. doi: 10.1016/j.jsat.2015.04.010. Epub 2015 May 7.

15.

Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.

Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, Olsen YK, Jaffe JH.

J Psychoactive Drugs. 2015 Apr-Jun;47(2):149-57. doi: 10.1080/02791072.2015.1014948.

16.

Interview with Dr Jerome H Jaffe.

Jaffe JH.

Drug Alcohol Depend. 2015 Apr 1;149:290-1. No abstract available.

PMID:
25941692
17.

Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans.

Bershad AK, Jaffe JH, Childs E, de Wit H.

Psychoneuroendocrinology. 2015 Feb;52:281-8. doi: 10.1016/j.psyneuen.2014.12.004. Epub 2014 Dec 9.

18.

Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.

Mitchell SG, Gryczynski J, Kelly SM, O'Grady KE, Jaffe JH, Olsen YK, Schwartz RP.

J Drug Issues. 2014 Jan;44(1):69-82.

19.

Interim versus standard methadone treatment: a benefit-cost analysis.

Schwartz RP, Alexandre PK, Kelly SM, O'Grady KE, Gryczynski J, Jaffe JH.

J Subst Abuse Treat. 2014 Mar;46(3):306-14. doi: 10.1016/j.jsat.2013.10.003. Epub 2013 Oct 14.

20.

Leaving buprenorphine treatment: patients' reasons for cessation of care.

Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP.

J Subst Abuse Treat. 2014 Mar;46(3):356-61. doi: 10.1016/j.jsat.2013.10.004. Epub 2013 Oct 14.

21.

Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH; Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership.

Pain. 2013 Nov;154(11):2287-96. doi: 10.1016/j.pain.2013.05.053. Epub 2013 Jun 20. Review.

22.

Schwartz et al. respond.

Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen YK, Mitchell SG, Jaffe JH.

Am J Public Health. 2013 Aug;103(8):e2-3. doi: 10.2105/AJPH.2013.301428. Epub 2013 Jun 13. No abstract available.

23.

Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, O'Grady KE, Olsen YK, Mitchell SG.

Am J Addict. 2013 May-Jun;22(3):285-91. doi: 10.1111/j.1521-0391.2012.12004.x.

24.

Retention in methadone and buprenorphine treatment among African Americans.

Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, Olsen YK, Schwartz RP.

J Subst Abuse Treat. 2013 Sep;45(3):287-92. doi: 10.1016/j.jsat.2013.02.008. Epub 2013 Apr 5.

25.

Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009.

Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH.

Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14.

26.

Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment.

Kelly SM, Oʼgrady KE, Jaffe JH, Gandhi D, Schwartz RP.

J Addict Med. 2013 Mar-Apr;7(2):133-8. doi: 10.1097/ADM.0b013e318284a0c1.

27.

A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.

Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, Olsen YK, Jaffe JH.

Drug Alcohol Depend. 2013 Mar 1;128(3):222-9. doi: 10.1016/j.drugalcdep.2012.08.027. Epub 2012 Sep 20. Erratum in: Drug Alcohol Depend. 2016 Nov 1;168:340.

28.

Joseph Vincent Brady (1922-2011): Behavioral neuropharmacologist, but so much more.

Jaffe JH.

Addiction. 2012 Jan;107(1):223-4. doi: 10.1111/j.1360-0443.2011.03688.x. No abstract available.

PMID:
22151322
29.

Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial.

Kelly SM, Schwartz RP, Oʼgrady KE, Gandhi D, Jaffe JH.

J Addict Med. 2012 Jun;6(2):145-52. doi: 10.1097/ADM.0b013e31823ae556.

30.

Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.

Schwartz RP, Kelly SM, O'Grady KE, Gandhi D, Jaffe JH.

Addiction. 2012 May;107(5):943-52. doi: 10.1111/j.1360-0443.2011.03700.x. Epub 2012 Feb 11.

31.

African American patients seeking treatment in the public sector: characteristics of buprenorphine vs. methadone patients.

Mitchell SG, Kelly SM, Gryczynski J, Myers CP, Jaffe JH, O'Grady KE, Olsen YK, Schwartz RP.

Drug Alcohol Depend. 2012 Apr 1;122(1-2):55-60. doi: 10.1016/j.drugalcdep.2011.09.009. Epub 2011 Sep 29.

32.

Patterns in admission delays to outpatient methadone treatment in the United States.

Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH.

J Subst Abuse Treat. 2011 Dec;41(4):431-9. doi: 10.1016/j.jsat.2011.06.005. Epub 2011 Aug 6.

33.

Interim methadone treatment compared to standard methadone treatment: 4-month findings.

Schwartz RP, Kelly SM, O'Grady KE, Gandhi D, Jaffe JH.

J Subst Abuse Treat. 2011 Jul;41(1):21-9. doi: 10.1016/j.jsat.2011.01.008. Epub 2011 Feb 24.

34.

A follow-up of vietnam drug users: origins and context of Lee Robins' classic study.

Jaffe JH.

Am J Addict. 2010 May-Jun;19(3):212-4. doi: 10.1111/j.1521-0391.2010.00043.x. No abstract available.

PMID:
20525025
35.

Impact of interim methadone maintenance on HIV risk behaviors.

Wilson ME, Schwartz RP, O'Grady KE, Jaffe JH.

J Urban Health. 2010 Jul;87(4):586-91. doi: 10.1007/s11524-010-9451-7.

36.

Scaling-up interim methadone maintenance: treatment for 1,000 heroin-addicted individuals.

Schwartz RP, Jaffe JH, O'Grady KE, Das B, Highfield DA, Wilson ME.

J Subst Abuse Treat. 2009 Dec;37(4):362-7. doi: 10.1016/j.jsat.2009.04.002. Epub 2009 Jun 21.

37.

Interim methadone treatment: impact on arrests.

Schwartz RP, Jaffe JH, O'Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A.

Drug Alcohol Depend. 2009 Aug 1;103(3):148-54. doi: 10.1016/j.drugalcdep.2009.03.007. Epub 2009 May 14.

38.

Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome.

Highfield DA, Schwartz RP, Jaffe JH, O'Grady KE.

Addiction. 2007 Nov;102(11):1816-23. Epub 2007 Sep 3.

PMID:
17784892
39.

Can LAAM, like Lazarus, come back from the dead?

Jaffe JH.

Addiction. 2007 Sep;102(9):1342-3. No abstract available.

PMID:
17697269
40.

A randomized controlled trial of interim methadone maintenance: 10-Month follow-up.

Schwartz RP, Jaffe JH, Highfield DA, Callaman JM, O'Grady KE.

Drug Alcohol Depend. 2007 Jan 5;86(1):30-6. Epub 2006 Jun 21.

PMID:
16793221
41.

Some day hence.

Jaffe JH.

Addiction. 2006 May;101(5):643-4; discussion 644-5. No abstract available.

PMID:
16669893
42.

Young heroin users in Baltimore: a qualitative study.

Gandhi DH, Kavanagh GJ, Jaffe JH.

Am J Drug Alcohol Abuse. 2006;32(2):177-88.

PMID:
16595322
43.

Do antagonists have a role in the treatment of opioid dependence?

Jaffe JH.

Addiction. 2006 Apr;101(4):468-9. No abstract available.

PMID:
16548923
44.

A randomized controlled trial of interim methadone maintenance.

Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O'Grady KE, Battjes RJ.

Arch Gen Psychiatry. 2006 Jan;63(1):102-9.

PMID:
16389204
45.

Learning from uncommon events: comment on Degenhardt et al. 2005.

Jaffe JH.

Addiction. 2005 Jul;100(7):921-2; discussion 930-2. No abstract available.

PMID:
15955000
46.

A postmarketing study of relative abuse liability of hypnotic sedative drugs.

Jaffe JH, Bloor R, Crome I, Carr M, Alam F, Simmons A, Meyer RE.

Addiction. 2004 Feb;99(2):165-73.

PMID:
14756709
47.

From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.

Jaffe JH, O'Keeffe C.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S3-11. Review.

PMID:
12738346
48.

Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users.

Gandhi DH, Jaffe JH, McNary S, Kavanagh GJ, Hayes M, Currens M.

Addiction. 2003 Apr;98(4):453-62.

PMID:
12653815
49.

Injectable opiate maintenance in the United Kingdom: a view from the United States.

Jaffe JH.

Addiction. 2001 Apr;96(4):557-60; discusion 564-5. No abstract available.

PMID:
11345076
50.

Conversation with Jerome H. Jaffe.

Jaffe JH.

Addiction. 1999 Jan;94(1):13-30. No abstract available.

PMID:
10665082

Supplemental Content

Loading ...
Support Center